Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Philippe Moreau et al.|New England Journal of Medicine|2023Cited by 719
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji Kumar, Philippe Moreau, Simon J. Harrison et al.|The Lancet Oncology|2020Cited by 401
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Jamie Cavenagh, Sarah Brown et al.|The Lancet Haematology|2016Cited by 43
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (<scp>MUK</scp> six open label, multi‐centre phase I/<scp>II</scp> Clinical Trial)Rakesh Popat, Jamie Cavenagh, Louise Flanagan et al.|British Journal of Haematology|2018Cited by 8